• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
Citation: JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
shu

Research progress on stimulator of interferon genes agonists for cancer immunotherapy

More Information
    Graphical Abstract
    • Abstract
  • In recent years, tumor immunotherapy has become a new hot spot in the field of cancer treatment. Besides the great success of immunological checkpoint inhibitors and cellular immunotherapy, small molecule immunotherapy has also attracted more and more attention. As a key signal transduction molecule involved in the innate immune response, stimulator of interferon genes plays an important role in defending against viral and intracellular bacterial infections, mediating type I IFN production and regulating the production of spontaneous anti-tumor immune responses in vivo. This paper briefly introduces the biological mechanism of STING signaling pathway and reviews the research progress of STING agonists based on the structural classification, so as to provide some reference for the design and discovery of STING agonist drugs.
    • FullText(HTML)
    • References (44)
  • [1]
    Ishikawa H,Ma Z,Barber GN.STING regulates intracellular DNA-mediated,type I interferon-dependentinnate immunity[J].Nature,2009,461(7265):788-792.
    [2]
    Ma Z,Damania B.The cGAS-STING defense pathway and its counteraction by viruses[J].Cell Host Microbe,2016,19(2):150-158.
    [3]
    Wang Z,Celis E.STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice[J]. Cancer Immunol Immunother,2015,64(8):1057-1066.
    [4]
    Tang CA,Zundell JA,Ranatunga S,et al.Agonist-mediated activation of STING induces apoptosis in malignant B CElls[J].Cancer Res,2016,76(8):2137-2152.
    [5]
    Demaria O, De GA, Coso S, et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity[J].Proc Natl Acad Sci U S A,2015,112(50):15408-15413.
    [6]
    Ishikawa H,Barber GN.STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling[J].Nature,2008,455(7213):674-678.
    [7]
    Zheng Y,Xing YL,Cheng XJ,et al.Regulation of innate immunity signaling by STING,a stimulator of interferon genes[J].Prog Biochem Biophys(生物化学与生物物理进展),2013,40(1):5-14.
    [8]
    Ding L,Ni YH,Hu QG,et al.cGAS-STING:the novel mechanism of cytosolic DNA sensing pathways[J].Prog Biochem Biophys(生物化学与生物物理进展),2014,41(9):830-838.
    [9]
    Gao P,Ascano M,Zillinger T,et al.Structure-function analysis of STING activation by c[G(2′,5′)pA(3′,5′)p] and targeting by antiviral DMXAA[J].Cell,2013,154(4):748-762.
    [10]
    Ramanjulu JM,Pesiridis GS,Yang JS,et al.Design of amidobenzimidazole STING receptor agonists with systemic activity[J].Nature,2018,564(7736):439-443.
    [11]
    Cai X,Chiu YH,Chen ZJ.The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling[J].Mol Cell,2014,54(2):289-296.
    [12]
    Xiao TS,Fitzgerald KA.The cGAS-STING pathway for DNA sensing[J].Mol Cell,2013,51(2):135-139.
    [13]
    Shang G,Zhang C,Chen ZJ,et al.Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP[J].Nature,2019,567(7748):389-393.
    [14]
    Zhang C,Shang G,Gui X,et al.Structural basis of STING binding with and phosphorylation by TBK1[J].Nature,2019,567(7748):394-398.
    [15]
    Woo SR,Fuertes MB,Corrales L,et al.STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors[J].Immunity,2014,41(5):830-842.
    [16]
    Xia T,Konno H,Ahn J,et al.Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis[J].Cell Rep,2016,14(2):282-297.
    [17]
    Corrales L,Glickman LH,Mcwhirter SM,et al.Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity[J].Cell Rep,2015,11(7):1018-1030.
    [18]
    Ohkuri T,Ghosh A,Kosaka A,et al.STING contributes to anti-glioma immunity via triggering type-I IFN signals in the tumor microenvironment[J].Cancer Immunol Res,2014,2(S3):1199-1208.
    [19]
    Yue XH,Ye JQ,Sun LP.Biological functions and related diseases of STATs[J].J China Pharm Univ(中国药科大学学报),2016,47(4):404-411.
    [20]
    Deng L,Liang H,Xu M,et al.STING-Dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors[J].Immunity,2014,41(5):843-852.
    [21]
    Burdette DL, Monroe KM, Sotelo-Troha K, et al. STING is a direct innate immune sensor of cyclic di-GMP[J].Nature,2011,478(7370):515-518.
    [22]
    Kato K, Omura H, Ishitani R, et al. Cyclic GMP-AMP as an endogenous second messenger in innate immune signaling by cytosolic DNA[J].Annu Rev Biochem,2017,86:541-566.
    [23]
    Berger G,Lawler SE.Novel non-nucleotidic STING agonists for cancer immunotherapy[J].Future Med Chem,2018,10(24):2767-2769.
    [24]
    Li L,Yin Q,Kuss P,et al.Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs[J].Nat Chem Biol,2014,10(12):1043-1048.
    [25]
    Corrales L,Gajewski TF.Molecular pathways:targeting the stimulator of interferon genes(STING)in the immunotherapy of cancer[J].Clin Cancer Res,2015,21(21):4774-4779.
    [26]
    Fu J,Kanne DB,Leong M,et al.STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade[J].Sci Transl Med,2015,7(283):283ra252.
    [27]
    ESMO 2018 Congress.New clinical findings involving STING agonist as monotherapy and in combination with an anti-PD-1 therapy[EB/OL].(2018-10-20)[2019-01-20] .https://www.mrknewsroom.com/news-release/oncology-newsroom/first-presentation-early-data-mercks-investigational-sting-agonist-mk.
    [28]
    Truong QT,Cumming JN,Altman MD,et al.Cyclic di-nucleotide compounds as STING agonists:WO,2017027645[P].2017-03-17[2019-01-20] .
    [29]
    Lim JW,Wu WL,Cumming JN,et al.Cyclic dinucleotide derivatives are STING agonists-useful for treating cell proliferation disorders,such as cancers:WO,2018208667[P].2018-10-16[2019-01-20] .
    [30]
    Biggadike K,Coe DM,Needham D,et al.Cyclic dinucleotides useful for the treatment of inter alia cancer:WO,2016120305[P].2015-04-15[2019-01-20] .
    [31]
    Yang JS,Adam M,Clemens J,et al.Preclinical characterization of GSK532,a novel STING agonist with potent anti-tumor activity[J].Clin Res,2018,78(13):5554.
    [32]
    American Association for Cancer Research(AACR)Special Conference on Tumor Immunology and Immunotherapy.Positive preclinical findings support advancement of SB-11285 into further development as a potential immunotherapeutic agent in cancer[EB/OL].(2016-10-20)[2019-01-20] .https://www.marketwatch.com/press-release/spring-bank-pharmaceuticals-presents-data-on-sting-agonist-sb-11285-at-the-aacr-special-conference-on-tumor-immunology-and-immunotherapy-2016-10-20.
    [33]
    33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer(SITC 2018).Preclinical characterization of BMS-986301,a differentiated STING agonist with robust antitumor activity as monotherapy or in combination with anti-PD-1[EB/OL].(2018-11-06)[2019-01-20] .https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220479/.
    [34]
    BrumL JR, Canham S, Kanne DB, et al. Locked nucleic acid cyclic dinucleotide compounds and uses thereof:WO,2018009466[P].2018-01-11[2019-01-20] .
    [35]
    Carotta S,Fleck M,Oost T,et al.Cyclic dinucleotide compounds:WO,2018060323[P].2018-04-05[2019-01-20] .
    [36]
    Lioux T,Mauny MA,Lamoureux A,et al.Design,synthesis,and biological evaluation of novel cyclic adenosine-inosine monophosphate(cAIMP)analogs that activate stimulator of interferon genes(STING)[J].J Med Chem,2016,59(22):10253-10267.
    [37]
    Plowman J,Narayanan VL,Dykes D,et al.Flavone acetic acid:a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice[J].Cancer Treat Rep,1986,70(5):631-635.
    [38]
    Liu JJ,Ching LM,Goldthorpe M,et al.Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours[J].Cancer Chemother Pharmacol,2007,59(5):661-669.
    [39]
    Corrales L,Gajewski TF.Molecular pathways:targeting the stimulator of interferon genes(STING)in the immunotherapy of cancer[J].Clin Cancer Res,2015,21(21):4774-4779.
    [40]
    Lu M,Tyagarajan S,Cash BD,et al.Benzo[b]thiophene compounds as STING agonists:WO,2018067423[P].2018-04-07[2019-01-20] .
    [41]
    Trotter BW,Kopinja JE,Tse ANC,et al.Combinations of PD-1 antagonists and benzo[b]thiophene STING agonists for cancer treatment:WO,2019027858[P].2019-02-08[2019-01-20] .
    [42]
    Sali TM, Pryke KM, Jinu A, et al. Characterization of a novel human-specific STING agonist that elicits antiviral activity against emerging alphaviruses[J].PLoS Pathog,2015,11(12):e1005324.
    [43]
    Kimura Y,Negishi H,Matsuda A,et al.Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways[J].Cancer Sci,2018,109(9):2687-2696.
    [44]
    Liu B,Tang L,Zhang X,et al.A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists[J].Antiviral Res,2017,147:37-46.
    • Related Articles

  • Related Articles

    [1]YANG Qian, CHEN Nannan, YOU Qidong, XU Xiaoli. Research progress on stimulator of interferon genes (STING) agonists[J]. Journal of China Pharmaceutical University, 2022, 53(3): 253-263. DOI: 10.11665/j.issn.1000-5048.20220301
    [2]CHU Xuxin, BU Fanxue, YIN Tingjie, HUO Meirong. Antitumor strategies based on targeted modulation of tumor-associated macrophages[J]. Journal of China Pharmaceutical University, 2021, 52(3): 261-269. DOI: 10.11665/j.issn.1000-5048.20210301
    [3]QIAO Yixue, MOU Yi, HUANG Zhangjian, AI Yong, KANG Fenghua, LAI Yisheng, ZHANG Yihua. Synthesis and antitumor activities of novel CDDO-Me analogues[J]. Journal of China Pharmaceutical University, 2015, 46(3): 289-293. DOI: 10.11665/j.issn.1000-5048.20150305
    [4]XU Yue, YUE Jiping, YANG Xianyu. Research advances in antitumor peptides of Anuran[J]. Journal of China Pharmaceutical University, 2014, 45(5): 587-592. DOI: 10.11665/j.issn.1000-5048.20140515
    [5]CHENG Haibo, XU Bin, ZHANG Huibin, ZHOU Jinpei. Synthetic process of antitumor drug dacomitinib[J]. Journal of China Pharmaceutical University, 2014, 45(2): 165-169. DOI: 10.11665/j.issn.1000-5048.20140206
    [6]HU Kun, ZHOU Anfei, JIANG Hefei, XU Yuanyuan, HUANG Qianhui, YANG Jie, CHEN Xin, REN Jie. Synthesis and antitumor activities of podophyllotoxin derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(1): 33-38. DOI: 10.11665/j.issn.1000-5048.20140105
    [7]LI Linhu, CHEN Li, XIA Yufeng. Progress in the study of coumarin derivatives as antitumor agents[J]. Journal of China Pharmaceutical University, 2013, 44(4): 374-379. DOI: 10.11665/j.issn.1000-5048.20130417
    [8]REN Jie, CHENG Hong, WANG Wei, HU Kun. Synthesis and antitumor activity of novel chrysin derivatives[J]. Journal of China Pharmaceutical University, 2011, 42(3): 206-212.
    [9]HUANG Fang-fang, YANG Yong-fang, DING Guo-fang. Advances in the study of antitumor activities of the marine mollusks extracts[J]. Journal of China Pharmaceutical University, 2009, 40(3): 284-288.
    [10]ZHOU Mei, MA Lin, HAO Xiao-jiang, YANG Xiao-sheng. Antitumor activities of chemical constituents of Cephalotaxus fortunei in Guizhou province[J]. Journal of China Pharmaceutical University, 2009, 40(3): 209-212.

  • Cited by

    Periodical cited type(2)

    1. 李焱琳，王琪. 干扰素介导肿瘤免疫分子机制的相关研究进展. 临床合理用药. 2025(02): 177-180 .
    2. 梅家豪，洪泽，王琛. 靶向cGAS-STING信号通路药物的研究进展. 中国药科大学学报. 2020(03): 249-259 . 本站查看

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (914) PDF downloads (1567) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302641

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return